1. You are here:
  2. Research
  3. Research Articles
  4. 2021 Articles

2021 Articles

Accepted articles

In vitro metabolism of the REV-ERB agonist SR-9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples.
Cutler C, White D, Viljanto M.
Drug Test. Anal., DOI 10.1002/dta.3124.

Multidose pharmacokinetics and safety of a modified, compounded theophylline product in dogs.
Reinhart JM, Perkowski C, Lester C, Campos V, Kadotani S, Li Z, McKiernan BC, Fries R.
J. Vet. Pharmacol. Ther., DOI 10.1111/jvp.12997.

Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration.
Homedes J, Salichs M, Solà J, Menargues A, Cendrós JM, Encina G.
J. Vet. Pharmacol. Ther., DOI 10.1111/jvp.12995.

Pharmacokinetics of transdermal flunixin meglumine and effects on biomarkers of inflammation in horses.
Knych HK, Arthur RM, Gretler SR, McKemie DS, Goldin S, Kass PH.
J. Vet. Pharmacol. Ther., DOI 10.1111/jvp.12993.

Control of gene doping in human and horse sports.
Tozaki T, Hamilton NA.
Gene Ther., DOI 10.1038/s41434-021-00267-5.

Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control.
Schenk I, Machnik M, Broussou D, Meuly A, Roques BB, Lallemand E, Düe M, Röttgen H, Lagershausen H, Toutain PL, Thevis M.
J. Vet. Pharmacol. Ther., DOI 10.1111/jvp.12991.

Long-term detection of clodronate in equine plasma by liquid chromatography-tandem mass spectrometry.
Garcia P, Perot I, Loup B, Balssa F, Jaubert M, Delcourt V, Dujardin C, Popot MA, Bailly-Chouriberry L.
Drug Test. Anal., DOI 10.1002/dta.3050.

Establishment of a post-race biomarkers database and application of pathway analysis to identify potential biomarkers in post-race equine plasma.
Ohnuma K, Uchida T, Leung GN, Ueda T, Obara T, Ishii H.
Drug Test. Anal., DOI 10.1002/dta.3041.

Plasma and urine pharmacokinetics of two formulations of dexamethasone in greyhound dogs.
Morris T, Paine SW, Zahra P, Li E, Colgan S, Karamatic S.
J. Vet. Pharmacol. Ther., DOI 10.1111/jvp.12970.

A quick approach for medetomidine enantiomers determination in dog plasma by chiral LC-MS/MS and application to a pharmacokinetic study.
Bardhi A, Zaghini A, Levionnois O, Barbarossa A.
Drug Test. Anal., DOI 10.1002/dta.3015.

The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses.
Skrzypczak H, Reed R, Brainard B, Sakai D, Barletta M, Quandt J, Smyth C, Ruch M, Kynch H.
Equine Vet. J., DOI 10.1111/evj.13424.

Systemic detectability of dexamethasone and prednisolone after eye drop application in horses.
Stucki M, Voegel CD, Binz TM, Kraemer T, Lavaud A, Voelter K.
Equine Vet. J., DOI 10.1111/evj.13418.

Published articles

Plasma levels of a methadone constant rate infusion and their corresponding effects on thermal and mechanical nociceptive thresholds in dogs.
Amon T, Kästner SBR, Kietzmann M, Tünsmeyer J.
BMC Vet. Res., 2021, 17, 35.

The effect of serial administration of bicarbonate on plasma total CO2 concentrations in horses.
Bailey SR, Forbes G, Selvadurai N, McLarney K, Jones S, Steel CM.
Drug Test. Anal., 2021, 13, 397–403.

Investigation of equine in vivo and in vitro derived metabolites of the selective androgen receptor modulator (SARM) ACP-105 for improved doping control.
Broberg MN, Knych H, Bondesson U, Pettersson C, Stanley S, Thevis M, Hedeland M.
Metabolites, 2021, 11, 85.

Quantification of 17 endogenous and exogenous steroidal hormones in equine and bovine blood for doping control with UHPLC-MS/MS.
Caprioli G, Genangeli M, Mustafa AM, Petrelli R, Ricciutelli M, Sagratini G, Sartori S, Laus F, Vittori S, Cortese M.
Pharmaceuticals (Basel), 2021, 14, 393.

A duplex qPCR assay for human erythropoietin (EPO) transgene to control gene doping in horses.
Cheung HW, Wong KS, Lin VYC, Wan TSM, Ho ENM.
Drug Test. Anal., 2021, 13, 113–121.

Label-free proteomics for discovering biomarker candidates of RAD140 administration to castrated horses.
Cheung HW, Wong KS, To NS, Bond AJ, Farrington AF, Prabhu A, Curl P, Wan TSM, Ho ENM.
Drug Test. Anal., 2021, 13, 1034–1047.

Equine metabolism of the selective androgen receptor modulator AC‐262536 in vitro and in urine, plasma and hair following oral administration.
Cutler C, Viljanto M, Taylor P, Habershon‐Butcher J, Muir T, Biddle S, Van Eenoo P.
Drug Test. Anal., 2021, 13, 369–385.

Unravelling androgens in sport: Altrenogest shows strong activation of the androgen receptor in a mammalian cell bioassay.
Gillon A, Ho ENM, Chan GHM, Kauff A, Hughes G, Lund RA, Ashley Z, Wan TSM, Heather AK.
Drug Test. Anal., 2021, 13, 523–528.

Novel algorithms for comprehensive untargeted detection of doping agents in biological samples.
Guan F, You Y, Fay S, Li X, Robinson MA.
Anal. Chem., 2021, 93, 7746–7753.

Stability of ketoprofen methylester in plasma of different species.
Hu SX, Ernst K, Benner CP, Feenstra KL.
Curr. Drug Metab., 2021, 22, 215–223.

Detection and longitudinal distribution of GW1516 and its metabolites in equine hair for doping control using liquid chromatography - high-resolution mass spectrometry.
Ishii H, Shibuya M, Leung GNW, Nozawa S, Yamashita S, Yamada M, Kushiro A, Kasashima Y, Okada J, Kawasaki K, Kijima-Suda I.
Rapid Commun. Mass Spectrom., 2021, 35, e9050.

Metabolic study of GW1516 in equine urine using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometer for doping control.
Ishii H, Shibuya M, Leung GNW, Yamashita S, Yamada M, Kushiro A, Kasashima Y, Okada J, Kawasaki K, Kijima-Suda I.
Rapid Commun. Mass Spectrom., 2021, 35, e9028.

Metabolism and excretion of the benzodiazepine analog etizolam in the horse.
Johnson E, van Heemst J, Benavides J, Gray B.
Drug Test. Anal., 2021, 13, 583–594.

In vitro metabolism of slowly cleared GPR139 agonist TAK-041 using rat, dog, monkey and human hepatocyte models (HepatoPac): correlation with in vivo metabolism.
Kamel A, Bowlin S, Hosea N, Arkilo D, Laurenza A.
Drug Metab. Dispos., 2021, 49, 121–132.

Towards an untargeted mass spectrometric approach for improved screening in equine anti-doping.
Keen B, Cawley A, Fouracre C, Pyke J, Fu S.
Drug Test. Anal., 2021, 13, 1001–1007.

Pharmacokinetic analysis of two different doses of simvastatin following oral administration in dogs.
Kim MS, Baek IH.
J. Vet. Pharmacol. Ther., 2021, 44, 333–341.

Determination of the route of excretion of robenacoxib (Onsior™) in cats and dogs: A pilot study.
King JN, Jung M.
J. Vet. Pharmacol. Ther., 2021, 44, 411–416.

Finding the proverbial needle: Non-targeted screening of synthetic opioids in equine plasma.
Klingberg J, Cawley A, Shimmon R, Fouracre C, Pasin D, Fu S.
Drug Test. Anal., 2021, 13, 977–989.

Single‐dose pharmacokinetics of mycophenolic acid following administration of immediate‐release mycophenolate mofetil in healthy beagle dogs.
Klotsman M, Sathyan G, Anderson WH.
J. Vet. Pharmacol. Ther., 2021, 44, 650–656.

Pharmacokinetics and anti-inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses.
Knych HK, Arthur RM, McKemie DS, Baden RW, Seminoff K, Kass PH.
Equine Vet. J., 2021, 53, 102–116.

Identification and characterization of the enzymes responsible for the metabolism of the non‐steroidal anti‐inflammatory drugs, flunixin meglumine and phenylbutazone, in horses.
Knych HK, Finno CJ, Baden R, rthur RM, McKemie DS.
J. Vet. Pharmacol. Ther., 2021, 44, 36–46.

Species difference in hydrolysis of an ester-type prodrug of levodopa in human and animal plasma: Different contributions of alpha-1 acid glycoprotein.
Kono K, Nunoya KI, Nakamura Y, Bi J, Mukunoki A, Takeo T, Nakagata N, Hitoshi M, Yamaura Y, Imawaka H, Watanabe H, Maruyama T.
Mol. Pharm., 2021, 18, 1985–1991.

Application of a non-target variable data independent workflow (vDIA) for the screening of prohibited substances in doping control testing.
Leung DKK, Wong ASY, Zhou QL, Wan TSM, Ho ENM.
Drug Test. Anal., 2021, 13, 1008–1033.

Quantitative determination of AZD3264, a selective Ikb-kinase IKK2 inhibitor, in dog plasma by solvent-induced phase transition extraction coupled with HPLC-MS/MS and its application to pharmacokinetic study in dogs.
Li G, Liang S, Qiao K, Wang C.
J. AOAC Int., 2021, 104, 348–354.

A sensitive HPLC-MS/MS method for the detection, resolution and quantitation of cathinone enantiomers in horse blood plasma and urine.
Loganathan D, Yi R, Patel B, Zhang J, Kong N.
Anal. Bioanal. Chem., 2021, 413, 2147–2161.

Identification of HIF stabilizer roxadustat and its possible metabolites in Thoroughbred horses for doping control.
Mathew B, Philip M, Perwad Z, Karatt TK, Caveney MR, Subhahar MB, Karakka Kal AK.
Drug Test. Anal., 2021, 13, 1203–1215.

Oral pharmacokinetics in beagle dogs of the mitragynine metabolite, 7-hydroxymitragynine.
Maxwell EA, King TI, Kamble SH, Raju KSR, Berthold EC, León F, Hampson A, McMahon LR, McCurdy CR, Sharma A.
Eur. J. Drug Metab. Pharmacokinet., 2021, 46, 459–463.

A validated method for the quantification of IOX-2, a potent prolyl hydroxylase inhibitor in equine urine and plasma using liquid chromatography-high-resolution mass spectrometry.
Mikhail E, Siccardi E, Bawazir A, Rajesh A, Prathyush S, Al Wazani DMK, Sabeek M, John T.
Drug Test. Anal., 2021, 13, 1178–1190.

Evaluation of dried blood spots as an alternative sample matrix for equine anti-doping analysis.
Moeller BC, Yang Z.
Drug Test. Anal., 2021, 13, 386–396.

Doping detection in animals: A review of analytical methodologies published from 1990 to 2019.
Moreira F, Carmo H, de Pinho PG, de Lourdes Bastos M.
Drug Test. Anal., 2021, 13, 474–504.

Preliminary bioequivalence of an oral integrating film formulation containing meloxicam with a suspension formulation in beagle dogs.
Park JS, Kim S, Lee J, Choi JC, Kim Y, Park CW, Lee S.
J. Vet. Pharmacol. Ther., 2021, 44, 342–348.

Metabolic studies of HIF stabilizers IOX2, IOX3, and IOX4 (in vitro) for doping control.
Philip M, Mathew B, Karatt TK, Perwad Z, Subhahar MB, Karakka Kal AK.
Drug Test. Anal., 2021, 13, 794–816.

Pharmacokinetics of acetaminophen after intravenous and oral administration in fasted and fed Labrador retriever dogs.
Sartini I, Łebkowska-Wieruszewska B, Lisowski A, Poapolathep A, Cuniberti B, Giorgi M.
J. Vet. Pharmacol. Ther., 2021, 44, 28–35.

Pharmacokinetics and pharmacodynamics of intravenous continuous rate infusion and repeated intramuscular administration of dexmedetomidine in standing horses.
Shane SE, Langston VC, Wills RW, Denney WS, Knych H, Fontenot RL, Meyer RE, Natalini CC.
J. Vet. Pharmacol. Ther., 2021, 44, 533–543.

Metabolic studies of selective androgen receptor modulators RAD140 and S-23 in horses.
So YM, Wong JKY, Choi TLS, Prabhu A, Stewart B, Farrington AF, Robinson P, Wan TSM, Ho ENM.
Drug Test. Anal., 2021, 13, 318–337.

Detection and identification of ACP‐105 and its metabolites in equine urine using LC/MS/MS after oral administration.
Subhahar MB, Karakka Kal AK, Philip M, Karatt TK, Ibrahimwaseem N., Vazhat RA, Muhammed Ajeebsanu M.P.
Drug Test. Anal., 2021, 13, 299–317.

Comprehensive characterization of the PPAR-δ agonist GW501516 for horse doping control analysis.
Trevisiol S, Moulard Y, Delcourt V, Jaubert M, Boyer S, Tendon S, Haryouli H, Taleb W, Caroff M, Chabot B, Drif L, André F, Garcia P, Loup B, Barnabé A, Popot MA, Bailly-Chouriberry L.
Drug Test. Anal., 2021, 13, 1191–1202.

Concentration profiles and safety of topically applied betulinic acid and NVX‐207 in eight healthy horses—A randomized, blinded, placebo‐controlled, crossover pilot study.
Weber LA, Puff C, Kalbitz J, Kietzmann M, Feige K, Bosse K, Rohn K, Cavalleri JMV.
J. Vet. Pharmacol. Ther., 2021, 44, 47–57.

Quantitation of apremilast in beagle dogs plasma by UPLC-MS-MS and iIts application to pharmacokinetic studies.
Xiong W, Wang L, Zhang H, Tao X, Jiang X, Liu Z, Zhao J, Xu W.
J. Anal. Methods Chem., 2021, 8881076.

Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction.
Yang Y, Li X, Zhou Q, Sun L, Zhang T.
J. Pharm. Biomed. Anal., 2021, 193, 113668.

Use of high resolution/accurate mass full scan/data-dependent acquisition for targeted/non-targeted screening in equine doping control.
You Y, Proctor RM, Guo K, Li X, Xue E, Guan F, Robinson MA.
Anal. Methods, 2021, 13, 1565–l1575.

Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in rats, dogs, and humans.
Yue Q, Khojasteh SC, Cho S, Ma S, Mulder T, Chen J, Pang J, Ding X, Deese A, Pellet J, Siebers N, Joas L, Salphati L, Ware J.
Xenobiotica, 2021, 51, 796–810.